Clinical Trial Update: Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for sorafenib in metastatic or recurrent esophageal and gastroesophageal junction cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Cancer, Gastroesophageal Junction Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-03-13